Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Canada has enhanced its Caregiver-Friendly Pharmacy (CFP) program by introducing new mental health support resources for caregivers, recognizing the pandemic's toll on them. Launched on National Caregiver Day, these resources underscore the pivotal role of Canada's eight million unpaid caregivers. Teva's research highlights that 43% of the global population identifies as caregivers, yet many lack adequate support. Key offerings include a partnership with Huddol for a resilience-building class and a 30-day free trial of the Huddol Journeys App, aiming to empower caregivers in their challenging roles.

Teva Pharmaceuticals USA has launched the first generic version of AZOPT (brinzolamide ophthalmic suspension) 1%, approved by the FDA to treat ocular hypertension and open-angle glaucoma. This product provides patients with an affordable treatment option, with annual U.S. sales over $184 million. Teva holds the largest FDA-approved generic portfolio, with nearly 550 products available. This launch demonstrates Teva's commitment to expanding access to essential medicines while maintaining a leading position in the generics market.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on March 2, 2021, at 8:30 a.m. Eastern Time. Investors can access a live webcast on Teva’s Investor Relations website. An archived presentation will be available shortly after the session. Teva, a leader in generic and specialty medicines, has over 3,500 products serving approximately 200 million people globally daily. For more information, visit www.tevapharm.com.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has published an in vitro study in Cephalalgia examining the differences in mechanisms between various CGRP-targeting drugs. The study indicates that AJOVY (fremanezumab) selectively targets the CGRP ligand, while other therapies may bind to multiple receptors, potentially leading to off-target effects. The research highlights significant biological variances in targeting CGRP ligands versus receptors, though clinical implications remain uncertain. AJOVY is the first long-acting anti-CGRP injection approved in the U.S. and EU for migraine prevention.

Teva Pharmaceutical Industries Ltd. reported Q4 and FY 2020 results, with Q4 revenues at $4.5 billion and FY 2020 revenues at $16.7 billion. Key highlights include non-GAAP EPS of $0.68 for Q4 and $2.57 for FY 2020. The company anticipates 2021 revenue between $16.4 billion and $16.8 billion, with non-GAAP EPS projected between $2.50 and $2.70. Despite experiencing a 1% revenue decline from 2019, gross profit increased by 3%, attributed to higher sales from AUSTEDO and AJOVY. Teva also reported cash flow from operations of $1.216 billion in 2020.

Teva Pharmaceuticals USA has launched a generic version of NuvaRing (etonogestrel and ethinyl estradiol vaginal ring) in the U.S. This AB-rated and bioequivalent contraceptive is now part of Teva’s extensive generic portfolio, enhancing access to women's health options. Teva currently offers over 550 FDA-approved generic medicines and leads in first-to-file opportunities with more than 100 pending in the U.S. The annual sales for etonogestrel and ethinyl estradiol products exceed $837 million, highlighting the market potential for this generic launch.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will announce its fourth quarter and full year 2020 financial results on February 10, 2021, at 7:00 a.m. ET. Following the release, a conference call will occur at 8:00 a.m. ET, with access numbers provided for participants. The call can also be streamed live via Teva's website. The company emphasizes its century-long commitment to medicine development, with over 3,500 products and a vast supply chain serving about 200 million people globally.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced that President & CEO Kåre Schultz will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 8:20 A.M. Eastern Time. Investors can access the live webcast via Teva’s Investor Relations website. An archived version will be available one hour post-session. Teva is a global leader in generic and specialty medicines, with over 3,500 products. Approximately 200 million people rely on Teva medicines daily, supported by a complex supply chain.

Teva Pharmaceuticals and MedinCell announced positive results from the RISE study, a Phase 3 trial of TV-46000/mdc-IRM, an extended-release injectable for schizophrenia. Patients receiving the treatment experienced a statistically significant delay in relapse compared to placebo, with reductions of 80.0% and 62.5% for monthly and bi-monthly doses, respectively (p<0.0001). No new safety concerns arose. Teva plans to continue leading development and regulatory processes for commercialization, while MedinCell will receive milestones and royalties.